In the Journals

Dry eye signs, symptoms improve with re-esterified omega-3

Researchers confirmed the improvement in the signs and symptoms for dry eye after 12 weeks and support the recommendation that dietary supplementation of re-esterified omega-3 fatty acids should be included as a primary therapy, according to a study in Cornea.

The multicenter, placebo-controlled, double-masked study involved 105 subjects randomized to receive four softgels containing a total of 1,680 mg of eicosapentaenoic acid/560 mg of docosahexaenoic acid or a control of 3,136 mg of linoleic acid, daily for 12 weeks. Mean patient age was 56.8 years, with 54 subjects randomized to omega-3 group and 51 subjects to the control group.

Tear osmolarity, tear break-up time (TBUT), matrix metalloproteinase-9 (MMP-9) and Ocular Surface Disease Index (OSDI) symptoms scores all improved at 12 weeks compared to the control group.

In the omega-3 group, a reduction of 16.8 mOsm/L vs. 9.0 mOsm/L was observed at week 6 and 19.4 mOsm/L at week 12.

Statistically significant increases in omega-3 index levels and TBUT were also found.

Researchers also reported OSDI score reduction in omega-3 of 17.0 vs. the control group at 5.0.

The omega-3 group experienced a 67.9% reduction in MMP-9 positivity in a 12-week period, whereas the control group experienced a 35% decrease throughout the same time period, according to the study.

The researchers wrote that improved tear film quality and stability may result in less visual fluctuation. – by Abigail Sutton

Disclosure: Epitropoulos received compensation from PRN Physician Recommended Nutraceuticals for participating in the study. Please see the full study for remaining authors’ financial disclosures.

Researchers confirmed the improvement in the signs and symptoms for dry eye after 12 weeks and support the recommendation that dietary supplementation of re-esterified omega-3 fatty acids should be included as a primary therapy, according to a study in Cornea.

The multicenter, placebo-controlled, double-masked study involved 105 subjects randomized to receive four softgels containing a total of 1,680 mg of eicosapentaenoic acid/560 mg of docosahexaenoic acid or a control of 3,136 mg of linoleic acid, daily for 12 weeks. Mean patient age was 56.8 years, with 54 subjects randomized to omega-3 group and 51 subjects to the control group.

Tear osmolarity, tear break-up time (TBUT), matrix metalloproteinase-9 (MMP-9) and Ocular Surface Disease Index (OSDI) symptoms scores all improved at 12 weeks compared to the control group.

In the omega-3 group, a reduction of 16.8 mOsm/L vs. 9.0 mOsm/L was observed at week 6 and 19.4 mOsm/L at week 12.

Statistically significant increases in omega-3 index levels and TBUT were also found.

Researchers also reported OSDI score reduction in omega-3 of 17.0 vs. the control group at 5.0.

The omega-3 group experienced a 67.9% reduction in MMP-9 positivity in a 12-week period, whereas the control group experienced a 35% decrease throughout the same time period, according to the study.

The researchers wrote that improved tear film quality and stability may result in less visual fluctuation. – by Abigail Sutton

Disclosure: Epitropoulos received compensation from PRN Physician Recommended Nutraceuticals for participating in the study. Please see the full study for remaining authors’ financial disclosures.